Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848608 | 0.86 | LMNA (0.75) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13571406 | 0.84 | LMNA (0.62) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13570747 | 0.83 | KDM4E (0.74) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13571368 | 0.83 | LMNA (0.61) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13639895 | 0.82 | KDM4E (0.67) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13571160 | 0.81 | LMNA (0.57) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13571615 | 0.81 | HTT (0.72) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13570909 | 0.81 | KDM4E (0.58) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL13571263 | 0.81 | LMNA (0.61) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 | |
| SCHEMBL20597937 | 0.80 | KDM4E (0.79) | LMNAKDM4ESMN1; SMN2RAB9AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520575-B1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | GEN INC ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8796320-B2 | 1,3,4-Oxadiazole-2-carboxamide compound | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20120302524-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2520575-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | General Incorporated Association Pharma Valley Project Supporting Organization (JP) | 2012-11-07 | — | — | EP | disclosed |
| CN-102725287-A | 1,3, 4-oxadiazole-2-carboxamide compounds | PHARMA IP GENERAL INC ASS | 2012-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302524-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | STAT3, JAK2, STAT5A | LMNA 4594/4885KDM4E 480/4885SMN1; SMN2 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.